



## **QuickCheck<sup>TM</sup>** Norditropin<sup>®</sup> (somatropin) injection benefits verification in ~4 hours

= required field

ENT	First name	Last name		Bi	irth date	//	
PATIENT INFORMATIO	Street address		City, State			Zip	
PRIMARY INSURANCE INFORMATION	Please attach copies of both insurance cards or provide insurance information below.						
	Primary insurance holder name Phone # ( )						
	Medical insurance company	Member ID	Member ID		Group ID		
	Insurance phone ()	Bin #	Bin #				
	(if available)	(if available)					
	Medical group (IPA)						
			Member ID Group ID_				
	Insurance phone ()	Bin #					
	(if available) Person code #	(if available) PCN	(if available) PCN				
	Insurance phone () Bin #						
	What is the primary diagnosis for which you are prescribing Norditropin <sup>®</sup> ? ( <i>required</i> )						
DIAGNOSIS	Adult Growth Hormone Deficiency (GHD):	Small for Gestati	•	) ∣ Noonan Syndrome	· ·		
	E23.0-Hypopituitarism		ature/growth failure	<ul> <li>Q87.89-Other specified congenital malformation syndromes, not elsewhere classified or Q89.8-Other specified congenital malformations or Q87.1-Congenital malformation syndromes predominantly associated with short stature</li> <li>Prader-Willi Syndrome:</li> <li>Q87.89-Other specified congenital malformation syndromes, not elsewhere classified or Q89.8-Other specified congenital malformation syndromes of the specified congenital malformation syndromes of the specified congenital malformation or Q89.8-Other specified congenital malformaticon or Q89.8-Other specified congenital malformation or Q89.8-O</li></ul>			
	E23.1-Drug-induced hypopituitarism or	PLUS					
	E89.3-Postprocedural hypopituitarism		orn affected by slow				
	Pediatric GHD:	intrauterine g P05.10-Newb					
	<ul> <li>E23.0-Hypopitaliansin</li> <li>E23.1-Drug-induced hypopituitarism or E89.3-Postprocedural hypopituitarism</li> </ul>	gestational ag	gestational age, unspecified weight pathic Short Stature:				
		R62.52-Short st					
		Turner Syndrome	-		Q87.1-Congenital malformation syndromes		
	Other diamonia	Q96.9-Turner's	syndrome, unspecified	predominantly associated with short stature			
	Other diagnosis: ICD-10 code and description:						
PRODUCT TO CHECK/ DOSING	Norditropin <sup>®</sup> FlexPro <sup>®</sup> ( <i>required</i> )			Dosing:			
		🔲 15 mg/1.5 mL (NDC 0169-7708-21)		Daily dose	mg/	day	
	10 mg/1.5 mL (NDC 0169-7705-21)	-	30 mg/3 mL (NDC 0169-7703-21)				
	Physician release: By signing this QuickCheck <sup>™</sup> Form, I hereby certify the following: (a) I am a licensed practitioner in good standing under state law; (b) the above therapy is medically necessary; and (c) the information						
PHYSICIAN INFORMATION AND RELEASE	I have provided on this QuickCheck <sup>™</sup> Form is, to the best of my knowledge, true, complete, and accurate in all respects. I further certify that, pursuant to the Health Insurance Portability and Accountability Act, 45 C.F.R. Parts 160 and 164 ("HIPAA"), I have obtained prior express authorization from the above named patient, or where						
	appropriate the patient's Legal Guardian, in the form of a written consent or express waiver that is legally sufficient under HIPAA, which permits the use or disclosure of the above named patient's above protected health information ("PHI") or other limited, but necessary, information, to Novo Nordisk Inc., its employees, or partners, including RxCrossroads, LLC (collectively, "NovoCare®"), for the sole purpose of providing assistance in						
	obtaining coverage for Novo Nordisk human growth hormone products, as well as assistance in initiating or continuing therapy. I further agree that I will immediately notify NovoCare® if the above named patient, or where appropriate the patient's Legal Guardian, revokes their consent to share their PHI with NovoCare®.						
N AI	Accordingly, I appoint NovoCare $^{\otimes}$ , on my behalf, to convey this prescription of the transmission of transmission of the transmission of transmission	tion to the dispensing pharmacy					
МАТК	Health care professional signature	Date	NPI #		Tax ID #		
NFOR	Health care professional name (please print)	City, State			( <u>)</u> Phone numl	ber	
CIANI	Preferred mode of contact:	🗆 Email			() Fax number		
ISYHA	Nurse or office contact name						
_	Office name						

Norditropin® and FlexPro® are registered trademarks and QuickCheck<sup>™</sup> is a trademark of Novo Nordisk Health Care AG. NovoCare<sup>®</sup> is a registered trademark of Novo Nordisk A/S. Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2020 Novo Nordisk All rights reserved. NC122020-12 December 2020